SCHEMBL4908412

SCHEMBL4908412

Cc1ccc(-c2nc(NC3CC3)nc(SCC(N)=O)c2C#N)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.50
KDM4E B2RXH2 6/20 0.50
HPGD P15428 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
GLA P06280 1/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 3/20 0.45
ADORA2B P29275 3/20 0.43
HTR1B P28222 1/20 0.43
OPRK1 P41145 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
HSD17B10 Q99714 3/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
BRAF P15056 1/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907216 0.83 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL4908408 0.83 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL4909720 0.82 MAPT (0.51) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL4897863 0.81 BACE1 (0.47) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL4907483 0.79 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL4907550 0.78 BRAF (0.42) ADORA2BADORA2ABRAFPDE4APDE4B
SCHEMBL4900982 0.78 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL4909704 0.76 ADORA2B (0.44) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL4907249 0.76 KMT2A (0.41) ALDH1A1HPGDMEN1KMT2AADORA2B
SCHEMBL4907060 0.73 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ALDH1A1 1662/4885KDM4E 2429/4885HPGD 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.